Login to Your Account



Kidney Cancer Data, News On Filing Hurt Onyx Stock

By Randall Osborne


Tuesday, October 26, 2004
Effectively handicapping themselves in the race with Pfizer Inc. to get a kidney cancer drug to market, Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. said they plan to pursue FDA clearance of their drug based on results from an ongoing Phase III trial rather than data gleaned from the Phase II study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription